Key Insights

Highlights

Success Rate

81% trial completion

Published Results

12 trials with published results (25%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.4%

5 terminated out of 48 trials

Success Rate

81.5%

-5.0% vs benchmark

Late-Stage Pipeline

13%

6 trials in Phase 3/4

Results Transparency

55%

12 of 22 completed with results

Key Signals

12 with results81% success

Data Visualizations

Phase Distribution

32Total
Not Applicable (5)
P 1 (12)
P 2 (9)
P 3 (4)
P 4 (2)

Trial Status

Completed22
Unknown9
Terminated5
Active Not Recruiting4
Withdrawn3
Not Yet Recruiting2

Trial Success Rate

81.5%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (48)

Showing 20 of 20 trials
NCT05356858Phase 2TerminatedPrimary

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

NCT00716066Phase 2Active Not Recruiting

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT01623076Active Not RecruitingPrimary

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

NCT04201262Phase 3CompletedPrimary

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT00445367Active Not Recruiting

Biobank For MS And Other Demyelinating Diseases

NCT07159893Not ApplicableNot Yet RecruitingPrimary

Inectolizumab With Steroid Optimization in Newly Treated NMOSD

NCT05828212Phase 1CompletedPrimary

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica

NCT06398158RecruitingPrimary

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

NCT05982925Enrolling By Invitation

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

NCT04614454Phase 2CompletedPrimary

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

NCT05566769Not ApplicableRecruitingPrimary

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

NCT05403138Phase 2Active Not RecruitingPrimary

Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

NCT04155424Phase 2TerminatedPrimary

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

NCT06497374Phase 2Not Yet RecruitingPrimary

FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack

NCT04629274Not ApplicableCompletedPrimary

In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO

NCT03062579Phase 1Completed

A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

NCT03766347CompletedPrimary

Pediatric NMOSD Observational Study

NCT06118398UnknownPrimary

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

NCT03942952Completed

PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.

NCT02865018Phase 1CompletedPrimary

Neuromyelitis Optica (NMO) & Cetirizine

Scroll to load more

Research Network

Activity Timeline